European HeadquartersNews & Events
Rare Disease Cures Accelerator-Data and Analytics Platform First Year Milestones Highlighted at Virtual Workshop
C-Path, NORD, FDA and more come together to showcase the importance of data sharing in rare disease drug development TUCSON, Ariz. and WASHINGTON, D.C. October 21, 2020 — The Critical Path Institute (C-Path) and the National Organization for Rare Disorders (NORD®) hosted the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) 2020 Virtual Workshop on […]
Biomarkers of Crohn’s Disease to Support the Development of New Therapeutic Interventions
C-Path’s Crohn's Disease Biomarkers Pre-Consortium funded by The Helmsley Charitable Trust is proud to announce its first publication in the journal Inflammatory Bowel Diseases titled, "Biomarkers of Crohn’s Disease to Support the Development of New Therapeutic Interventions." The result of collaboration among experts in Crohn’s disease, including academia, health care institutes, foundations, public advocacy groups, industry and regulatory bodies, this work has identified biomarkers that can be used as drug development tools to advance clinical trials in IBD and potentially improve patient care.
C-Path Data Collaboration Center Analytics Team Wins Metadata Automation DREAM Challenge
TUCSON, Ariz., July 14, 2020 — Tucson-based Critical Path Institute (C-Path) today proudly announced that the analytics team from its Data Collaboration Center (DCC) program has won first place in the validation phase of the Metadata Automation DREAM Challenge, funded by the Cancer Moonshot℠ initiative. The mission of C-Path’s DCC program is to provide large-scale data collaboration […]
C-Path Launches CURE Drug Repurposing Collaboratory to Accelerate Identification of New Uses of Existing Drugs to Treat Infectious Diseases, Including COVID-19
As millions of patients struggle with diseases that lack adequate treatments, there is a critical need to understand how existing drugs can be used in new ways to improve clinical outcomes. Health care professionals use drugs in novel ways as a potential life-saving intervention when no specific approved therapies are available. However, without the ability to share these experiences in a systematic manner, the clinical and research communities cannot benefit from lessons learned.
Stay connected with C-Path
C-Path Successes
- >>First preclinical safety biomarkers (7) qualified by the FDA, EMA and PMDA
- >>First imaging biomarker for trial enrichment qualified by the EMA
- >>FDA and EMA reach landmark decisions on C-Path’s Simulation Tool for Alzheimer’s disease
- >>C-Path’s Alzheimer’s Disease Simulator Featured in the Wall Street Journal
- >>C-Path and CDISC partnership delivers therapeutic area standards
- >>FDA and EMA issue first-of-their-kind Letters of Support for two Kidney Biomarkers
- >>EMA Qualifies ‘Hollow Fiber System’ For Anti-Tuberculosis Drug Development
- >>Regulatory Support For Autosomal Dominant Polycystic Kidney Disease Biomarker
- >>C-Path’s PKDOC Secures FDA Qualification for Enrichment Biomarker in ADPKD
- >>C-Path’s PKDOC Secures EMA Qualification Opinion for Enrichment Biomarker in ADPKD